Inhaled Corticosteroids and the Lung Microbiome in COPD

Area of Science:

• Pulmonary Medicine
• Microbiology
• Pharmacology

Background:

• Inhaled corticosteroids (ICS) are recommended for frequent exacerbations in chronic obstructive lung disease (COPD), especially with eosinophilic inflammation.
• Real-world data show ICS overuse in COPD, increasing risks like respiratory infections, highlighting a need for better biomarkers and optimal use strategies.
• The lung microbiome's role in COPD inflammation is emerging, with alterations linked to disease progression and exacerbations.

Purpose of the Study:

• To investigate the intricate relationship between the lung microbiome, inflammation, inhaled corticosteroid (ICS) use, and disease phenotype in COPD patients.
• To explore how ICS may influence airway microbiota composition and potentially increase the risk of adverse events.
• To identify potential biomarkers that could inform the benefit-risk assessment of ICS in personalized COPD management.

Main Methods:

• Utilizing next-generation sequencing to analyze changes in lung microbiome composition in COPD patients.
• Correlating microbiome alterations with inflammatory markers, ICS treatment history, and clinical COPD phenotypes.
• Evaluating the impact of ICS on bacterial load and the abundance of specific pathogenic taxa.

Main Results:

• COPD progression and exacerbation frequency are associated with significant shifts in lung microbiome composition.
• Inhaled corticosteroids (ICS) can promote potentially harmful changes in airway microbiota, including increased bacterial load and abundance of pathogens like *Streptococcus* and *Haemophilus*.
• A complex interplay exists between the microbiome, inflammation, ICS use, and COPD disease presentation.

Conclusions:

• The lung microbiome is a critical factor in COPD pathogenesis and response to therapy.
• Understanding the microbiome's interaction with ICS is essential for refining treatment guidelines and avoiding overuse.
• Personalized pharmacological management of COPD may be achieved by considering individual microbiome profiles alongside inflammatory and clinical data.